Citizens Against Government Waste (CAGW) was disappointed to see that the Trump Administration announced on Thursday, July 19, that the Food and Drug Administration (FDA) is exploring ways to import lower cost drugs from foreign countries. Since most countries utilize price controls to determine a drug’s cost, the U.S. would simply be importing a bad […]
Centers for Medicare and Medicaid seeks to revise how Medicare will pay for outpatient drugs under the 340B drug discount program.
New final 340B drug discount rule from CMS could save Medicare beneficiaries an estimated $320 million in copayments in 2018 alone
On July 11 and 12, the House Ways and Means Committee marked up and passed 11 bills that will expand the use and availability of Health Savings Accounts (HSAs) for all Americans and would make other changes to the Patient Protection and Affordable Care Act (ACA), or Obamacare. The bills considered were: H.R. 6301, “To […]
Report demonstrates that the 340B drug discount program is out of control and in dire need of restructuring.
The Safety Net 340B drug program must clearly define eligible patients to help them and not fatten hospital coffers.
On March 8, Citizens Against Government Waste (CAGW), penned a blog which pointed out a harmful and major change to Medicare Part D that will cost pharmaceutical manufacturers far more than anticipated: $4.1 billion over 10 years, a 53 percent increase from the Congressional Budget Office’s (CBO) original score. Some may think whacking pharmaceutical manufacturers […]
On Friday, May 11, President Trump released his report on what his administration will do to lower drug costs.
As the May 18 deadline for negotiating a modernized North American Free Trade Agreement (NAFTA) looms, negotiators should consider closely how intellectual property (IP) rights will be treated between the countries involved. According to the Global Innovation Policy Center’s (GIPC) 2018 International IP Index, which measures 50 countries against 40 IP indicators, the U.S. ranked […]
The President has already made some good policy decisions and has offered other proposals that will help to lower drug costs.
